ERBB2 and breast carcinoma: Recently, findings from the SOLAR-I trial showed that the PI3Kα inhibitor alpelisib nearly doubles median progression free survival in hormonal receptor positive/HER2 negative breast cancer when given together with the antiestrogen fulvestrant to patients with PIK3CA-mutant disease while no effect was seen in patients without a PIK3CA mutation [9].